Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

APPY 0.335 +0.011 (3.40%)
price chart
Company Shares of Venaxis, Inc. (NASDAQ:APPY) Drops by -14.63%
Venaxis, Inc. (NASDAQ:APPY) has lost 14.63% during the past week and dropped 13.37% in the last 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 13.45%.
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Related articles »  
Company Shares of Venaxis, Inc. (NASDAQ:APPY) Drops by -0.99%
Venaxis, Inc. (NASDAQ:APPY) has dropped 0.99% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 1.26% in the last 4 weeks.
Venaxis, Inc. Price Target Update
Venaxis, Inc. shares have received a Mean Price Target of $0.75. According to the rating issued from 2 Wall Street Analysts, the High Price Target is seen at $1 while the Lower end of the Price Target is seen at $0.5.
Company Shares of Venaxis, Inc. (NASDAQ:APPY) Rally 4.7%
Shares of Venaxis, Inc. (NASDAQ:APPY) rose by 4.7% in the past week and 8.16% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 8.39% and the outperformance increases to 16.96% for the last 4 weeks.
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Venaxis Business Update
CASTLE ROCK, Colo., June 22, 2015 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, ...
Venaxis, Inc. Short Interest Update
The short interest in Venaxis, Inc. (NASDAQ:APPY) has declined from 1,226,842 on August 31,2015 to 1,203,133 on September 15,2015.
Mid-Day Changers: ProShares Ultra Silver (AGQ), Venaxis, Inc. (APPY), Chicago ...
Venaxis, Inc. (APPY) of the Healthcare sector (Diagnostic Substances) has a change of 4.63% per at mid-day today. Venaxis, Inc. (APPY) is currently at $0.34, at a volume of 22,769 shares and a weekly performance of - 1.82%. Venaxis, Inc. (APPY)'s ...
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent” Response
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Venaxis' appendicitis test not found equivalent to standard care  Reuters